首页> 美国卫生研究院文献>Experimental Biology and Medicine >Regulation of mitophagy by the ubiquitin pathway in neurodegenerative diseases
【2h】

Regulation of mitophagy by the ubiquitin pathway in neurodegenerative diseases

机译:在神经退行性疾病中泛素途径对线粒体的调控

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mitophagy is a cellular process by which dysfunctional mitochondria are degraded via autophagy. Increasing empirical evidence proposes that this mitochondrial quality-control mechanism is defective in neurons of patients with various neurodegenerative diseases such as Ataxia Telangiectasia, Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Accumulation of defective mitochondria and the production of reactive oxygen species due to defective mitophagy have been identified as causes underlying neurodegenerative disease pathogenesis. However, the reason mitophagy is defective in most neurodegenerative diseases is unclear. Like mitophagy, defects in the ubiquitin/26S proteasome pathway have been linked to neurodegeneration, resulting in the characteristic protein aggregates often seen in neurons of affected patients. Although initiation of mitophagy requires a functional ubiquitin pathway, whether defects in the ubiquitin pathway are causally responsible for defective mitophagy is not known. In this mini-review, we introduce mitophagy and ubiquitin pathways and provide a summary of our current understanding of the regulation of mitophagy by the ubiquitin pathway. We will then briefly review empirical evidence supporting mitophagy defects in neurodegenerative diseases. The review will conclude with a discussion of the constitutively elevated expression of ubiquitin-like protein Interferon-Stimulated Gene 15 (ISG15), an antagonist of the ubiquitin pathway, as a potential cause of defective mitophagy in neurodegenerative diseases.Impact statementNeurodegenerative diseases place an enormous burden on patients and caregivers globally. Over six million people in the United States alone suffer from neurodegenerative diseases, all of which are chronic, incurable, and with causes unknown. Identifying a common molecular mechanism underpinning neurodegenerative disease pathology is urgently needed to aid in the design of effective therapies to ease suffering, reduce economic cost, and improve the quality of life for these patients. Although the development of neurodegeneration may vary between neurodegenerative diseases, they have common cellular hallmarks, including defects in the ubiquitin-proteasome system and mitophagy. In this review, we will provide a summary of our current understanding of the regulation of mitophagy by the ubiquitin pathway and discuss the potential of targeting mitophagy and ubiquitin pathways for the treatment of neurodegeneration.
机译:线粒体吞噬是一种细胞过程,通过它可以通过自噬降解功能异常的线粒体。越来越多的经验证据表明,这种线粒体质量控制机制在患有各种神经退行性疾病(例如共济失调毛细血管扩张症,阿尔茨海默氏病,帕金森氏病和肌萎缩性侧索硬化症)的患者的神经元中存在缺陷。线粒体缺陷引起的线粒体积累和活性氧的产生已被确定为潜在的神经退行性疾病发病机理。然而,线粒体在大多数神经退行性疾病中存在缺陷的原因尚不清楚。像线粒体吞噬一样,泛素/ 26S蛋白酶体途径中的缺陷也与神经退行性疾病有关,导致在患病患者的神经元中经常出现特征性蛋白质聚集。虽然线粒体吞噬的开始需要功能性的泛素途径,但尚不清楚泛素途径中的缺陷是否是导致线粒体缺陷的原因。在本微型审查中,我们介绍了线粒体和泛素途径,并提供了我们目前对通过线粒体途径调控线粒体的理解的总结。然后,我们将简要回顾支持神经退行性疾病中线粒体缺陷的经验证据。综述将以泛素样蛋白干扰素刺激基因15(ISG15)(泛素途径的拮抗剂)的组成性高表达的讨论作为结论,该蛋白可能是神经退行性疾病线粒体缺陷的潜在原因。全球患者和护理人员的负担。仅在美国,就有超过六百万人患有神经退行性疾病,所有这些疾病都是慢性的,无法治愈的,并且病因未知。迫切需要找出支持神经退行性疾病病理的共同分子机制,以帮助设计有效的疗法来减轻这些患者的痛苦,降低经济成本并改善其生活质量。尽管神经退行性疾病的发展可能会有所不同,但它们具有共同的细胞标志,包括遍在蛋白-蛋白酶体系统和线粒体的缺陷。在这篇综述中,我们将总结我们目前对遍在蛋白途径对线粒体调控的理解,并讨论靶向线粒体和泛素途径在治疗神经变性方面的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号